Hims & Hers Health (NYSE:HIMS) Coverage Initiated at Morgan Stanley

Investment analysts at Morgan Stanley assumed coverage on shares of Hims & Hers Health (NYSE:HIMS) in a research note issued to investors on Tuesday, MarketBeat reports. The brokerage set an “overweight” rating and a $42.00 price target on the stock. Morgan Stanley’s price target would suggest a potential upside of 47.11% from the company’s previous close.

Other analysts have also issued reports about the company. Canaccord Genuity Group raised their target price on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. Piper Sandler restated a “neutral” rating and issued a $21.00 price objective (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. TD Cowen reissued a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. Finally, Bank of America cut shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their price objective for the stock from $32.00 to $18.00 in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $22.80.

Hims & Hers Health Trading Down 8.3 %

Shares of Hims & Hers Health stock opened at $28.55 on Tuesday. The stock has a market capitalization of $6.24 billion, a price-to-earnings ratio of 64.89 and a beta of 1.25. The firm’s 50-day moving average price is $25.46 and its two-hundred day moving average price is $21.19. Hims & Hers Health has a 1-year low of $8.09 and a 1-year high of $35.02.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. During the same period in the previous year, the business earned ($0.04) EPS. Hims & Hers Health’s revenue was up 77.1% compared to the same quarter last year. As a group, equities research analysts predict that Hims & Hers Health will post 0.29 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In related news, CEO Andrew Dudum sold 45,767 shares of the firm’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $16.33, for a total transaction of $747,375.11. Following the sale, the chief executive officer now owns 67,015 shares of the company’s stock, valued at approximately $1,094,354.95. This trade represents a 40.58 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Michael Chi sold 2,054 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $33.56, for a total value of $68,932.24. Following the sale, the insider now directly owns 184,947 shares in the company, valued at approximately $6,206,821.32. This represents a 1.10 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,143,575 shares of company stock valued at $27,724,979. 17.71% of the stock is currently owned by company insiders.

Institutional Trading of Hims & Hers Health

A number of large investors have recently bought and sold shares of the business. Nisa Investment Advisors LLC increased its position in shares of Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after acquiring an additional 1,603 shares in the last quarter. Quest Partners LLC boosted its stake in Hims & Hers Health by 5,944.1% in the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares during the period. CWM LLC increased its holdings in Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after purchasing an additional 1,054 shares in the last quarter. Van ECK Associates Corp bought a new position in Hims & Hers Health during the 2nd quarter worth about $111,000. Finally, Quarry LP raised its stake in shares of Hims & Hers Health by 91.0% in the 3rd quarter. Quarry LP now owns 6,113 shares of the company’s stock valued at $113,000 after purchasing an additional 2,913 shares during the period. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.